Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.71 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.71 |
| ▸ | GCGR | P47871 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1207760 | 0.84 | GCGR (0.54) | MAPTNPSR1SAE1UBA2GCGR | |
| SCHEMBL2647883 | 0.83 | GCGR (0.73) | MAPTNPSR1SAE1UBA2GCGR | |
| SCHEMBL2649712 | 0.83 | GCGR (0.67) | MAPTNPSR1SAE1UBA2GCGR | |
| SCHEMBL1208011 | 0.82 | PTPN5 (0.51) | MAPTGCGRALDH1A1POLBHPGD | |
| SCHEMBL2648864 | 0.81 | GCGR (0.74) | MAPTNPSR1SAE1UBA2GCGR | |
| SCHEMBL2649274 | 0.81 | GCGR (0.76) | MAPTNPSR1SAE1UBA2GCGR | |
| SCHEMBL2649810 | 0.81 | MAPT (0.69) | MAPTNPSR1SAE1UBA2GCGR | |
| SCHEMBL2649360 | 0.78 | GCGR (0.72) | MAPTNPSR1SAE1UBA2GCGR | |
| SCHEMBL2647850 | 0.78 | GCGR (1.00) | MAPTNPSR1SAE1UBA2GCGR | |
| SCHEMBL2648262 | 0.78 | GCGR (0.72) | MAPTNPSR1SAE1UBA2GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060035958-A1 | Method of treating diabetes and related conditions | MERCK & CO., INC. | 2006-02-16 | — | — | US | claimed |
| EP-1538903-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004024066-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | claimed |
| US-20060035958-A1 | Method of treating diabetes and related conditions | MERCK & CO., INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1538903-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024066-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035958-A1 | Method of treating diabetes and related conditions | GLP1R, GPR119, GCGR | MAPT 4230/4885NPSR1 347/4885SAE1 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.